About one-third of the influenza B viruses tested this year are from the strain not included in this season’s trivalent vaccine; GlaxoSmithKline’s Fluarix is the second approved seasonal flu vaccine to protect against four virus strains, and by next season half of the U.S. manufacturers could be offering a broader spectrum product.
FDA’s approval of GlaxoSmithKline PLC’s Fluarix quadrivalent seasonal flu vaccine on Dec. 14 is speeding the move away from the current trivalent vaccine formulation.
GSK is the second company to get approval of a vaccine to protect against four influenza strains, and the first...